Firvanq Kit is a drug owned by Azurity Pharmaceuticals Inc. It is protected by 7 US drug patents filed from 2019 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 13, 2035. Details of Firvanq Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10959949 | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | Active |
| US11638692 | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | Active |
| US10493028 | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | Active |
| US10688046 | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | Active |
| US10959946 | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | Active |
| US10959947 | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | Active |
| US10959948 | Composition and method for vancomycin oral liquid |
Mar, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Firvanq Kit's patents.
Latest Legal Activities on Firvanq Kit's Patents
Given below is the list of recent legal activities going on the following patents of Firvanq Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Jan, 2024 | US10959947 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Jan, 2024 | US11638692 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Jan, 2024 | US10959948 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Jan, 2024 | US10493028 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Jan, 2024 | US10959946 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 23 Jan, 2024 | US10959949 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Dec, 2023 | US10688046 (Litigated) |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 11 Oct, 2023 | US10688046 (Litigated) |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 05 Jun, 2023 | US10493028 |
| Electronic Review Critical | 03 May, 2023 | US11638692 |
US patents provide insights into the exclusivity only within the United States, but Firvanq Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Firvanq Kit's family patents as well as insights into ongoing legal events on those patents.
Firvanq Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Firvanq Kit's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 13, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Firvanq Kit Generic API suppliers:
Vancomycin Hydrochloride is the generic name for the brand Firvanq Kit. 31 different companies have already filed for the generic of Firvanq Kit, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Firvanq Kit's generic
How can I launch a generic of Firvanq Kit before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Firvanq Kit's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Firvanq Kit's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Firvanq Kit -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 25 mg/mL and 50 mg/mL | 18 May, 2020 | 1 | 14 Nov, 2022 | 13 Mar, 2035 | Eligible |
Alternative Brands for Firvanq Kit
Firvanq Kit which is used for treating bacterial infections in the gastrointestinal tract., has several other brand drugs using the same active ingredient (Vancomycin Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Xellia Pharms Aps |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Vancomycin Hydrochloride, Firvanq Kit's active ingredient. Check the complete list of approved generic manufacturers for Firvanq Kit
About Firvanq Kit
Firvanq Kit is a drug owned by Azurity Pharmaceuticals Inc. It is used for treating bacterial infections in the gastrointestinal tract. Firvanq Kit uses Vancomycin Hydrochloride as an active ingredient. Firvanq Kit was launched by Azurity in 2018.
Approval Date:
Firvanq Kit was approved by FDA for market use on 26 January, 2018.
Active Ingredient:
Firvanq Kit uses Vancomycin Hydrochloride as the active ingredient. Check out other Drugs and Companies using Vancomycin Hydrochloride ingredient
Treatment:
Firvanq Kit is used for treating bacterial infections in the gastrointestinal tract.
Dosage:
Firvanq Kit is available in for solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 50MG BASE/ML | FOR SOLUTION | Prescription | ORAL |
| EQ 25MG BASE/ML | FOR SOLUTION | Prescription | ORAL |